Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9852W HIGH $5.67
Volume
2.94 K
Value Traded
2.59 K
Short % Float
0.58%
Days to Cover
1.0
-25.21%Week
-27.05%1 Month
-32.58%3 Month
-57.18%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.61 M
EPS (TTM)
-0.88
P/E Ratio
-
Ent. Value
-910.77 K
Total Shares
2.93 M
Float Shares
1.56 M
Insiders
46.92%
Institutions
0.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BGLC Catalyst Timeline
Dated clinical, regulatory and corporate events for BioNexus Gene Lab Corp
Past FDA Catalysts and PDUFA Decisions
How BGLC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
BioNexus Gene Lab Corp is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BGLC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BGLC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BGLC for Q2 2026. | ||||
BGLC Institutional Ownership Trends
BGLC Short Interest
Shares sold short, counted twice a month.
0.58%
Short % of Float
of tradable shares sold short
9.1K
Shares Sold Short
-10.5% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
13.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BGLC ranks across every disease it competes in
Competitive Position is a premium feature
See how BGLC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBGLC News
-BGLC
Oct 30, 2026▼ -9.2%today
BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
BioNexus Gene Lab Corp. launched a redesigned corporate website, enhancing resources for investors and partners. The site features information on its RNA screening business, industrial chemicals, and healthcare investments. An expanded investor-relations section offers access to reports and governance materials, improving communication and engagement.
Read more →-BGLC
Oct 7, 2026▲ +8.1%on this news
BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
BioNexus Gene Lab Corp. (BGLC) signed an exclusive license for Ruanyun Edai Technology’s CogniAI platform to build AI applications for Malaysian healthcare. The deal targets the government’s RM1 billion digitalization program covering 150 hospitals and over 2,000 clinics. BGLC will issue 560,000 shares for the rights, with closing pending technology delivery by December 2026.
Read more →-BGLC
Jul 28, 2026BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
BioNexus Gene Lab Corp. is advancing the commercialization of its VitaGuard MRD platform in Southeast Asia after a productive visit to China. The platform, which uses liquid biopsy technology, has received positive feedback from healthcare professionals. BioNexus aims to implement VitaGuard in select Southeast Asian markets by 2026, leveraging its exclusive rights in the region.
Read more →-BGLC
May 29, 2026BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
BioNexus Gene Lab Corp. is advocating for deeper biotechnology cooperation between Malaysia and China. During the 2026 China–Malaysia Economic Cooperation Outlook Forum, CEO Sam Tan highlighted the potential for a precision healthcare corridor. The company aims to move beyond traditional trade to foster co-development and commercialization of innovative healthcare technologies.
Read more →-BGLC
Mar 11, 2026BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of its VitaGuard MRD Platform
BioNexus Gene Lab Corp. has appointed Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to enhance the global commercialization of the VitaGuard MRD platform. Dr. Meyyappan brings over 15 years of experience in oncology diagnostics and genomics and will lead efforts to expand partnerships across international markets. This strategic move positions BioNexus as a key player in the rapidly growing field of minimal residual disease testing, furthering its aim to improve cancer detection and monitoring.
Read more →-BGLC
Feb 23, 2026BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
BioNexus Gene Lab Corp. has completed a governance restructuring of its subsidiary, Chemrex Corporation, streamlining its board to two directors and appointing Matthew Barsing as Chairman. This restructuring aims to enhance oversight and align with capital allocation strategies. The company is evaluating potential growth initiatives in biotechnology and healthcare infrastructure while maintaining a disciplined approach to capital management.
Read more →-BGLC
Jan 28, 2026BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
BioNexus Gene Lab Corp. (BGLC) has launched its 2026 Deployment Phase for the VitaGuard™ MRD platform, aiming to provide affordable cancer monitoring across Southeast Asia. The initiative targets a significant market gap by offering lower-cost alternatives to existing high-cost diagnostics. The company plans to integrate AI-assisted tools to enhance cancer care and generate valuable molecular datasets. BGLC's strategy focuses on sustainable market capture and building a recurring revenue model.
Read more →-BGLC
Dec 3, 2025BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™
BioNexus Gene Lab Corp. has completed a strategic investment in Fidelion Diagnostics, acquiring a 15% equity stake and exclusive rights for the VitaGuard™ platform in Southeast Asia. This partnership positions BGLC for growth in the precision oncology market. The deal is designed to enhance shareholder value while minimizing dilution.
Read more →-BGLC
Dec 2, 2025BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
BioNexus Gene Lab Corp. announced a $500 million equity facility from ARC Group International to support its expansion in precision diagnostics and CDMO operations. This funding will enhance the commercialization of the VitaGuard MRD platform and facilitate the development of therapeutic programs. The facility allows BGLC to access capital selectively for milestone-driven initiatives.
Read more →-BGLC
Dec 1, 2025BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard MRD Platform as Part of Strategic Alliance with Tongshu Gene
BioNexus Gene Lab Corp. (BGLC) has successfully signed an exclusive license agreement with Fidelion Diagnostics for the VitaGuard MRD platform, covering Southeast Asia. This agreement allows BGLC to manufacture, market, and sell VitaGuard-based products, positioning the company to lead in the underpenetrated area of MRD testing in the region. The deal is part of a broader strategic alliance that includes a previous shareholders' agreement with Tongshu Gene. Analysts predict significant growth in the liquid biopsy and MRD markets, suggesting a promising future for BGLC's operations in Southeast Asia.
Read more →-BGLC
Nov 13, 2025▼ -6.6%on this news
BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities
BioNexus Gene Lab Corp. has filed a $100 million shelf registration statement and established a $20 million at-the-market program to enhance its growth initiatives. This strategic move is aimed at advancing its operations in precision diagnostics and gene-based technologies across Asia and the U.S. The company anticipates that these financial instruments will facilitate partnerships with firms such as Fidelion Diagnostics and BirchBioMed. However, it acknowledges potential risks associated with regulatory approvals and market conditions that could impact its capital-raising efforts.
Read more →-BGLC
Nov 12, 2025▼ -6%on this newsshared move
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization
BioNexus Gene Lab Corp. (BGLC) has announced strategic agreements with Fidelion Diagnostics and Tongshu Biotechnology to commercialize the VitaGuard liquid-biopsy platform for minimal residual disease (MRD) testing in Southeast Asia. These agreements involve cross-equity alignment, with BGLC acquiring shares in Fidelion and securing exclusive commercialization rights across ASEAN. The collaboration aims to make high-fidelity, tumor-naive MRD testing more accessible in the region, with a focus on regulatory submissions and initial rollouts in Singapore and Malaysia. The VitaGuard technology is designed to detect ctDNA with high precision, potentially transforming cancer monitoring in routine clinical care.
Read more →-BGLC
Oct 20, 2025BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc. Collaboration Expected to Advance FS2 Topical Platform and Strengthen BGLC's Biotech Footprint in Asia Kuala Lumpu
BioNexus Gene Lab Corp has signed a non-binding strategic partnership term sheet with BirchBioMed Inc. to lead a $10 million financing round for Birch's FS2 topical platform. The collaboration aims to utilize BGLC's market access in Southeast Asia and Birch's advancements in dermal regeneration. As part of the arrangement, BGLC will provide expertise in clinical strategy and market intelligence. However, the partnership's non-binding nature raises questions about the certainty of future agreements.
Read more →-BGLC
Jul 30, 2025▲ +61%on this news
BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance-Touted as a new "DeepSeek Moment" in Precision Oncology
BioNexus Gene Lab Corp. (BGLC) and Fidelion Diagnostics have announced a strategic alliance focused on advancing precision oncology through the VitaGuard platform. This partnership allows BGLC to acquire equity in Fidelion and secure exclusive commercial rights for the VitaGuard minimal residual disease (MRD) platform in Southeast Asia. The collaboration aims to revolutionize cancer monitoring with lower costs and improved detection capabilities, potentially impacting millions of patients in the region. The announcement joins a trend of significant deal-making and investment in the biotech sector, particularly from China.
Read more →-BGLC
Apr 30, 2025BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness
BioNexus Gene Lab Corp. has announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), marking a significant step in the company's growth strategy. This compliance allows BGLC to pursue innovation, capital market engagement, and international expansion more effectively. The company is focused on expanding its genomic diagnostics and specialty materials, while also enhancing corporate governance to attract strategic partnerships and capital. The CEO expressed optimism about the future, highlighting investor confidence and the importance of the Nasdaq listing in their long-term strategy.
Read more →-BGLC
Apr 15, 2025▲ +7.7%on this news
BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory
BioNexus Gene Lab Corp. filed its 2024 Annual Report on Form 10-K with the SEC. The report covers the fiscal year ended December 31, 2024. The company highlighted its strategic innovation and operational resilience. This filing confirms the company's continued growth trajectory.
Read more →-BGLC
Mar 7, 2025▲ +7%on this news
BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy
BioNexus Gene Lab Corp has announced a strategic partnership with ML Tech to enhance its Ethereum-focused treasury strategy. The collaboration aims to leverage ML Tech's AI-driven wealth management platform to optimize BGLC's Ethereum holdings while maintaining strict risk management. Both companies emphasize the importance of technological innovation and transparency in their financial operations. However, the partnership is not without risks, as market conditions and regulatory changes may affect its outcomes.
Read more →-BGLC
Mar 5, 2025BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper
BioNexus Gene Lab Corp. (BGLC) has announced the approval of its Ethereum treasury strategy by its Board of Directors. This makes BGLC the first Nasdaq-listed company to prioritize Ethereum as a strategic asset, aligning with Ethereum's recent inclusion in the US 'Crypto Strategic Reserve.' The company also released its Ethereum Strategy Whitepaper, detailing the rationale behind the decision and Ethereum's significance as a financial infrastructure asset. The strategy aims to leverage Ethereum's strengths, including institutional adoption and staking capabilities, while benefiting from Wyoming's favorable blockchain regulations.
Read more →-BGLC
Sep 25, 2024BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd. Kuala Lumpur, Malaysia
BioNexus Gene Lab Corporation has partnered with Protech Builders Sdn. Bhd. to enter the biogas sector in Malaysia through a strategic teaming agreement. The two companies will collaborate to develop biogas plants that convert plantation wastewater into renewable energy. The partnership involves an initial financial commitment of up to RM1,000,000 for feasibility studies and project development. Both sides bring complementary expertise, with BioNexus providing market insights and Protech offering engineering capabilities, positioning them for success in the growing biogas market.
Read more →-BGLC
Sep 14, 2024▲ +11%on this news
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.
BioNexus Gene Lab Corp. has signed a strategic outsourcing agreement with VITARRAY Global Pte. Ltd. through its subsidiary, MRNA Scientific, to provide mRNA dynamic gene detection services for the Southeast Asian market. This agreement leverages MRNA Scientific's facilities in Kuala Lumpur and aims to enhance molecular diagnostics deployment. It includes provisions for reduced testing costs, facilitating market expansion, and maintaining confidentiality. The partnership is expected to improve early disease detection capabilities significantly in the region.
Read more →About BioNexus Gene Lab Corp
HeadquartersUNIT A-28-7, TOWER A, MENARA UOA BANGSAR, KUALA LUMPUR, 59000
BIOPHARMAWATCH ELITE PLUS
Trade the next BGLC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime